Emcure Pharmaceuticals has acquired Cutimed Inc, a Canadian company engaged in cosmetics and personal care products, for $2.8 million.
According to a BSE filing, the acquisition was made through Emcure’s step-down subsidiary, Mantra Pharma Inc. The move is expected to strengthen Emcure’s portfolio in the pharmaceuticals and healthcare sector.
The acquisition does not constitute a related party transaction, and neither the promoter nor the promoter group had any interest in Cutimed prior to the acquisition. The annual turnover of Cutimed is $2.8 million, with its primary market being Canada.
The project involves the acquisition of 100% of the issued and outstanding shares of Cutimed’s share capital. As part of the agreement, Cutimed has been amalgamated with Mantra Pharma Inc, effective April 1, 2026.
The order adds to Emcure’s growing portfolio of cosmetics and personal care products. The company’s move to acquire Cutimed is a strategic decision to expand its presence in the global market.
This acquisition reinforces Emcure’s position as a significant player in the pharmaceuticals and healthcare sector.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
